ERBB2 and neoplasm: Since the Lauren classification determines the treatment strategy (e.g., intestinal type is more responsive to chemotherapy, while diffuse type requires targeted approaches), studies in these journals help predict response to therapy (e.g., HER2-positive tumors are sensitive to trastuzumab), determine tumor aggressiveness (e.g., loss of E-cadherin in diffuse type is associated with a worse prognosis), and develop personalized treatment based on molecular profiling.